tbuckley/cabot-search huggingface dataset:
OP0035 Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate)
Authors: J.-E. Gottenberg, J. Morel, P. Ravaud, T. Bardin, P. Cacoub, A. Cantagrel, B. Combe, A. Constantin, M. Dougados, R.M. Flipo, B. Godeau, E. Hachulla, X. Le Loet, T. Schaeverbeke, J. Sibilia, I. Pane, G. Baron, X. Mariette
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To perform a joint analysis of the safety of abatacept (ABA), rituximab (RTX) and tocilizumab (TCZ) in real life. <h3>Methods</h3> The AIR, ORA and REGATE French Society of Rheumatology registries follow up prospectively patients with rheumatoid arthritis treated with RTX, ABA or TCZ. The analyses took into account serious infections that occurred in the 12 months that followed an infusion of rituximab in the absence of initiation of a new biologic or those who occurred under abatacept or tocilizumab or in the 3 months that followed their discontinuation, in the absence of initiation of a new biologic. Serious infections and cancers were validated by the review of the charts of patients. <h3>Results</h3> 1980 patients treated with RTX (current follow up of 6844 patient-years), 1024 patients with ABA (2882 patient-years), and 1503 patients with TCZ (1552 patient-years) (database of January 2013 for RTX and ABA and August 2013 for TCZ). – <i>Serious infections:</i> 309 serious infections occurred under RTX (4.5 serious infections/100 patient/years). 102 serious infections occurred under ABA (3.5 serious infections/100 patient/years). 55 serious infections occurred under TCZ (5.2 serious infections/100 patient/years). 3 tuberculosis infections (0.04/100 patient/years) occurred under RTX, 2 (0.07/100 patient/years) under ABA and no tuberculosis under TCZ. – <i>Cancers:</i> 85 cancers occurred under RTX (1.2/100 patient-years) including 14 non-melanoma skin cancers (0.2/100 patient/years), 71 solid cancers and haematological malignancies (1.0/100 patient/years) including 8 haematological malignancies (0.1/100/patient/years with 1 lymphoma).40 cancers occurred under ABA (1.4/100 patient/years) including 13 non-melanoma skin cancers (0.5/100 patient/years), 27 solid cancers and hematological malignancies (0.9/100 patients/year) including 4 haematological malignancies (0.14/100 patient/years, without lymphoma). 10 cancers were observed under TCZ (1.0/100 patient/years) including 2 non melanoma skin cancers (0.19/100/patient/years) 8 solid cancers and haematological malignancies 0.8/100 patient/years) including 3 haematological malignancies (0.29/100 patient/years) with 3 lymphomas. <h3>Conclusions</h3> Incidences of serious adverse events in real life patients with comorbidities were similar under ABA, RTX and TCZ to what is expected in rheumatoid arthritis treated with anti-TNF. With ABA, RTX and TCZ, the incidence of tuberculosis is low. Adjusted statistical comparisons of safety, efficacy and drug retention rate of these 3 biologics are currently performed. <h3>Disclosure of Interest</h3> None declared
Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy
Authors: Paul-Alain Jaffrès, Consuelo Gajate, Ana Maria Bouchet, Hélène Couthon-Gourvès, Aurélie Chantôme, Marie Potier-Cartereau, Pierre Besson, Philippe Bougnoux, Faustino Mollinedo, Christophe Vandier
Journal: Pharmacology & Therapeutics (2016)
THE PRESENT STATUS OF CANCER RESEARCH.
Authors: K Munk
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Soundings: Clients on diets
Authors: George Dunea
Journal: BMJ (2001)

So we worry about frightful epidemics, on television and in the newspapers, about the Black Death coming back or variola major rising from the dead, forgetting, in the midst of our recent preoccupations, about the deadliest scourge of all, more lethal than handguns and automobiles and anthrax all put together. It is food, food, the stuff that in the Hindu Kush we drop from planes in yellow packages but that here is a pathogen, causing this terrible epidemic of obesity, of coronary heart disease, of type 2 diabetes.

And so it came about, some 10 or 15 years ago (according to notes I found in an old file, and that I had made for a “Letter from . . . Chicago” that was never written) that the phone rang while I was in the middle of a busy outpatient clinic.

“It's about my client for whom you prescribed an 800 calorie diet.”

“You mean my patient,” I interjected.

“Well, we call them clients,” the voice said. “I think 800 calories is too little for my client.”

Defensively I suggested that 1000 calories might be sufficient to keep this 270 pound woman in metabolic balance.

“No,” said the voice, “at 1000 calories she will still need supplements; 1500 calories would be better.”

“Would you please do as I asked you?” I ventured.

“Oh no,” she said, “you do your doctoring, and I do the diet counselling.”

By now I could have hit her, had she not been at a safe distance. Instead I asked for her name, saying I would speak to her supervisor, whereupon she slammed the phone in my ear, and I let the matter go.

My feelings, moreover, were compounded by a certain amount of guilt, because somewhere in the dim past I was taught that it was the doctor's job to counsel patients about their diet. But things being as they are, I must also add that I have always felt sorry for dietitians because, despite their best efforts, most patients will still eat whatever they please.

I also find that many dietitians imagine indeed that we are in the Hindu Kush, and are more worried about starvation and deficiencies than about obesity. But I have stopped arguing with them. I now tell my overweight patients to listen politely, but then to eat half of what the dietitian prescribed.
Soundings: Hello again
Authors: Colin Douglas
Journal: BMJ (2004)

The handshake is unusual, now perhaps even more so: the Dupuytren's contracture he has had forever is worse. Even 20 years ago it was striking, but never got in the way of his legendary operating skills. Uncomplainingly, and effectively having only the thumbs and first two fingers of each hand to work with, he achieved near miracles and made them look easy.

As a teacher and then colleague he was revered. As a family, we owe him much. Why? His skills and judgment made our family possible.

He is older now, and less than happy. The NHS he loved and served has let him down. His wife—who knew what a hip fracture felt like because she had had one before—had been sent home from accident and emergency in great pain. When they came back again they had sat for four hours in the same department, and even after admission there were problems, some of them avoidable.

Our wonderful doctor is—briefly—an angry relative. In due course delays and difficulties are overcome. The patient makes progress; a clearly loving old couple are helped as they should have been from the beginning.

He shares his experiences. “The young man in complaints took it all down, and then I began to think about the staff. Not easy for them, I'm sure... `Don't worry,' the lad said. `We get dozens of complaints... Get them all the time... They're used to it.'” We are both laughing, in sheer despair.

A few days later he is again amused. “I walked into the ward as usual, and a patient—not my wife—shouted, `Hello, darling!' I really don't know what the other ladies must have thought...”

There is an entirely respectable explanation: his exuberant and long-serving ward sister, also a legend in her time, happens to have been admitted as well, and to a bed next to his wife. And she too has waited far too long for surgery.

His wife, our patient, had been a nurse once, trained in the 1940s. Briefly, in a corner of our hard-pressed modern ward, there is a strange little reunion, of three old people from a younger, happier NHS: an NHS they had served and loved; an NHS that served us so well when we needed it 20 years ago. Can we really be proud of how it is serving them now?
XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination
Authors: Hanna IJspeert, Jacob Rozmus, Klaus Schwarz, René L. Warren, David van Zessen, Robert A. Holt, Ingrid Pico-Knijnenburg, Erik Simons, Isabel Jerchel, Angela Wawer, Myriam Lorenz, Turkan Patıroğlu, Himmet Haluk Akar, Ricardo Leite, Nicole S. Verkaik, Andrew P. Stubbs, Dik C. van Gent, Jacques J. M. van Dongen, Mirjam van der Burg
Journal: Blood (2016)
Neoplasms in Tasmanian Devils (Sarcophilus harrisii)
Authors: L. A. Griner
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Neoplasms in Tasmanian Devils (Sarcophilus harrisii) Get access L. A. Griner L. A. Griner 2Pathology Department, Zoological Society of San Diego, P.O. Box 551, San Diego, Calif. 92112. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 62, Issue 3, March 1979, Pages 589–595, https://doi.org/10.1093/jnci/62.3.589 Published: 01 March 1979 Article history Received: 08 May 1978 Accepted: 11 September 1978 Published: 01 March 1979
The Incidence of Primary Carcinoma of the Liver in the Southern Bantu. II. Preliminary Report on Incidence in Johannesburg&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: A. G. Oettlé, J. Higginson
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article The Incidence of Primary Carcinoma of the Liver in the Southern Bantu. II. Preliminary Report on Incidence in Johannesburg Get access A. G. Oettlé, A. G. Oettlé South African Institute for Medical Research, Johannesburg, Trans-vaal, South Africa Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Higginson J. Higginson South African Institute for Medical Research, Johannesburg, Trans-vaal, South Africa Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 3, September 1956, Pages 281–287, https://doi.org/10.1093/jnci/17.3.281 Published: 01 September 1956 Article history Received: 17 May 1956 Published: 01 September 1956
The Role of Bile-Acid Derivatives in the Seroflocculation Reaction. I. Preparation of the Bile-Acid Derivatives&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;,&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: Harry S. Penn, M.D., Yoshitsugi Hokama, M.A.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article The Role of Bile-Acid Derivatives in the Seroflocculation Reaction. I. Preparation of the Bile-Acid Derivatives, Get access Harry S. Penn, M.D., Harry S. Penn, M.D. Associate Clinical Professor of Radiology (Oncology) Department of Radiology, University of California Medical Center, Los Angeles, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Yoshitsugi Hokama, M.A. Yoshitsugi Hokama, M.A. Graduate Research Microbiologist Department of Radiology, University of California Medical Center, Los Angeles, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 1, August 1955, Pages 225–235, https://doi.org/10.1093/jnci/16.1.225 Published: 01 August 1955 Article history Received: 25 June 1954 Published: 01 August 1955
THU0380 Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and its Clinic Significance
Authors: W. Kong, W. Deng, X. Feng, G. Yao, W. Chen, X. Tang, Y. Sun, S. Huang, Z. Zhang, B. Shi, L. Sun
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multiorgan impairment including glomerulonephritis, cutaneous lesions and arthritis. B cells participate in the onset of SLE. As a downstream signaling molecule of B-cell receptor (BCR) signaling pathway, Bruton tyrosine kinase (Btk) is involved in the development, activation and survival of B cells. It is reported that transgenic mice overexpressing Btk specifically in B cells could produce antinuclear antibody and develop a lupus-like symptoms. <h3>Objectives</h3> The aim of our study was to identify the specific role of Btk in lupus nephritis. <h3>Methods</h3> The percentages of Btk positive CD19+ B cells from 28 SLE patients and 28 healthy donors were examined by flow cytometry. The correlation between the percentages of Btk positive CD19+ B cells and some lupus related clinical indicators were analyzed. Immunohistochemistry was used to detect the Btk expression in kidney biopsies from 8 lupus nephritis (LN) patients and 8 controls. The levels of Btk expression in glomerulus were detected by image-pro plus analysis, and represented by mean optical density (MOD). <h3>Results</h3> The frequency of Btk+CD19+ B cells from SLE patients is up-regulated compared with the healthy controls (3.89±0.31 vs 2.61±0.21, <i>p</i>&lt;0.01), significantly correlating with the SLE activity (SLEDAI) (r=0.53), levels of serum anti-dsDNA antibody (r=0.41), levels of serum C3 (r=-0.41), and the amount of 24 hours urine protein (r=0.59). We also found that the frequency of Btk+CD19+ B cells in the patients with lupus nephritis was significantly higher compared with the patients without lupus nephritis (4.71±0.481 vs 3.19±0.30, <i>p</i>&lt;0.05). The levels of Btk expression in glomerulus were markedly increased in LN patients compared with controls (0.04±0.01 vs 0.01±0.00, <i>p</i>&lt;0.001). <h3>Conclusions</h3> Btk expression is significantly increased in LN, which may be a promising therapeutic target for the molecular therapy of SLE. <h3>Disclosure of Interest</h3> None declared
SP0191 Measuring Quality of Life in Young Adults with Jia in Clinical Practice
Authors: L. Haverman
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Children and adolescents with Juvenile Idiopathic Arthritis (JIA) are at risk for the development of psychosocial problems and a lowered Health Related Quality of Life (HRQOL). These problems are not always identified during consultations with a rheumatologist. Therefore, adequate screening, monitoring and providing tailored interventions is necessary. The goal of the KLIK program is therefore to monitor the HRQOL and psychosocial functioning of children and young adults with chronic illnesses over extended periods of time and to facilitate communication between patient and practitioner. Children (0-18 years) or their parents complete questionnaires on www.hetklikt.nu before a consultation. The basis of KLIK is a generic HRQOL questionnaire. The decision of disease-specific HRQOL and psychosocial questionnaires is based on focus groups with practitioners. The answers on the questionnaires (Patient Reported Outcomes) are converted into a KLIK ePROfile. The KLIK ePROfile consists of a literal representation of the answers and a graphic presentation. The KLIK ePROfiles are available prior to a consultation. The practitioner retrieves the ePROfile from the website and discusses this with the patient and parents. The KLIK program is effective in increasing discussion about emotional and psychosocial functioning in pediatric care. However, young adults can also benefit from the use of KLIK in adult care. The aim of this project is to adapt the KLIK program for young adults and facilitate transition. <h3>Methods</h3> To adapt the website for young adults (16-30 years) we will conduct focus groups in order to select the most important themes. To know where their major problems in psychosocial functioning and HRQOL are and to select the most suitable questionnaires for feedback in the KLIK program, we will conduct a cross-sectional study. After this we will change the lay-out of the website to make it more usable for young adults. <h3>Results</h3> Since implementation began in pediatric care in 2011, 31 patient groups, (including children with JIA) over 300 professionals in 8 different hospitals and around 3000 pediatric patients have started using KLIK in the Netherlands. The first steps in adapting KLIK for young adults are taken by conducting the first focus groups and by adding transition-specific questionnaires to the KLIK website. <h3>Conclusions</h3> The implementation of KLIK appears to be feasible and workable in pediatric care, and with information from focus groups, cross-sectional research and adaption of the website for young adults we will explore if the program is also feasible in adult care. <h3>Disclosure of Interest</h3> None declared
Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial.
Authors: J. T. Lettieri, A. L. Mazzu, L. Huang, C. D. Lathia
Journal: Journal of Clinical Oncology (2011)

2580 Background: This study was undertaken to examine the influence of mild/moderate hepatic impairment on the safety and pharmacokinetic (PK) profile of sorafenib in non-cancer subjects. Methods: This was a multicenter, open-label, controlled, single-dose, phase I study. Patients 50-75y were eligible if they had Child-Pugh (CP) class A or B hepatic impairment and body-mass index (BMI) >20 and ≤35. Age/gender–matched healthy volunteers with AST/ALT/LDH levels ≤1.2 times the upper limit of normal at screening were eligible as controls. Subjects received a single 400-mg dose of sorafenib under fasted conditions. Blood samples for PK analysis were collected just before dosing and at 1, 2, 3, 5, 7, 9, 12, 16, 24, 48, 72, 96, and 120 hours post-dose. Plasma was assayed for sorafenib and metabolites using a fully validated liquid chromatography/mass spectrometry assay. The primary PK assessments were AUC, Cmax, and t1/2. All subjects were monitored for adverse events (AEs). Results: Forty-five subjects were enrolled: 15 with CP A and 15 with CP B liver impairment, and 15 healthy volunteers. Age and gender distributions were similar for the three groups. Hepatitis C was the most common cause of hepatic dysfunction in the CP A (93%) and B (100%) groups. PK results for each cohort are shown in the table. There were no statistically significant differences in PK parameters between groups. Similar analysis of metabolites also revealed no significant differences between groups. Diarrhea was the most common treatment-emergent AE, occurring in 5 of the 45 subjects (4 in the CP B group and 1 in the control group). No new or unexpected AEs were observed. Conclusions: The PK profile of sorafenib is not significantly altered in the setting of CP A or B hepatic dysfunction. Based on these results, sorafenib dosage adjustment for mild/moderate hepatic impairment is not required. PK parameter Geometric mean, coefficient of variation (%) Child-Pugh A (N=15) Child-Pugh B (N=15) Healthy controls (N=15) AUC (mg•h/L) 124 (57) 107 (75) [n=14] 102 (67) Cmax (mg/L) 4.01 (67) 3.31 (50) 3.03 (59) t1/2 (hours) 27.5 (38) 27.9 (37) 27.0 (33)
PWE-082 ‘hot gall bladders’ – time to innovate?
Authors: G Goussous, J Spence, R Evans, F Iqbal, A Brook, A Rotundo, V Rao
Journal: Gut (2015)

<h3>Introduction</h3> Emergency admissions with gall bladder related symptoms account for significant component of acute surgical take in every busy surgical unit. There appears to be three subgroups of patients by way of presentation with implications towards appropriate management. Based on intra operative findings, an alternative model of management is proposed with implications towards potential savings in terms of inpatient stay. <h3>Method</h3> A prospective study of all consecutive acute admissions with gall bladder symptoms in a busy tertiary unit over a six month period was undertaken. Demographic data along with mode of presentation, inflammatory markers and intra operative findings were analysed. Differences in inflammatory markers between different subgroups were analysed using one way ANOVA. Total number of inpatient days were calculated and potential savings in terms of in patient days after applying the proposed new model of management was assessed. <h3>Results</h3> 145 patients (Age: 50; range:16–85, M:F = 44:101) were admitted with symptoms suggestive of gall bladder pathology over a six month period. Based on intra operative findings, three distinct groups of patients were recognised: biliary colic with thin walled gall bladder (n = 51), acute cholecystitis with thick walled inflamed gall bladder (n = 78) and complicated cholecystitis with empyema or localised perforation (n = 16). Excluding the patients with pancreatitis, there was significant difference in mean CRP levels between the three groups (biliary colic: 21.9, 95% confidence interval [CI] 9.0–34.8; acute cholecystitis: 85.1, 95% CI 58.4–111.7; complicated cholecystitis: 181.4, 95% CI 96.8–265.9, p = 0.000). There was also significant difference in mean WCC levels (biliary colic: 9.4, 95% CI 8.0–10.8; acute cholecystitis: 11.7, 95% CI 10.5–12.8; complicated cholecystitis: 13.9, 95% CI 11.8–16.0, p = 0.002). There was no difference in number of inpatient days and post op complications between the groups. The median length of stay was 7 (1–27) with the interval between admission and surgery being 4(1–15). There was no difference in number of inpatient days between the three subgroups. If the patients who had biliary colic and acute cholecystitis without pancreatitis were managed on an outpatient basis with deferred surgery on a day case basis, a saving of 594 inpatient days could be done with potential for significant savings for the NHS. <h3>Conclusion</h3> We suggest that those with biliary colic and acute cholecystitis can be managed on an out patient basis and have their surgery done on a day case basis within a reasonable time frame thereby saving a significant number of inpatient days. This has significant implications especially in times of increasing bed pressures in the NHS. <h3>Disclosure of interest</h3> None Declared.